A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
about
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studiesEffects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical updateCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsIncreased prolactin levels are associated with impaired processing speed in subjects with early psychosisA dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey.Auditory working memory impairments in individuals at familial high risk for schizophrenia.Mouse pharmacological models of cognitive disruption relevant to schizophrenia.Molecular targets for treating cognitive dysfunction in schizophrenia.Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.Evidence for an immune role on cognition in schizophrenia: a systematic reviewEffect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis.Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trialCognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophreniaPharmacotherapy for treatment-resistant schizophrenia.Quetiapine in the treatment of schizophrenia and related disorders.Notes from Underground: Are Cognitive-Enhancing Drugs Respecting their Promises?Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study.Cognitive decline in schizophrenia from childhood to midlife: a 33-year longitudinal birth cohort study.The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Neuropsychology, autobiographical memory, and hippocampal volume in "younger" and "older" patients with chronic schizophrenia.Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains.Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivityCognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.The impact of skills training on cognitive functioning in older people with serious mental illness.Current schizophrenia drugs: efficacy and side effects.Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review.Psychomotor slowing in schizophreniaToward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia.Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial.Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies.
P2860
Q22251051-E1B5444A-6C64-447F-86AE-45A98DB93C42Q26823735-167CCE7A-4ABB-49A5-AF34-AFC652577272Q27003099-986C2867-F25C-4313-BF6E-DED5BE9F7EE3Q28540093-E6FD1BA6-4976-409C-8BA8-2BD817C02D2DQ30356275-6E514B01-9BBF-40D7-B2B7-3A15996167A5Q30455072-B6A3F249-9B53-4872-B734-212BB16B741AQ30457807-C5286373-2C27-4855-82E6-4487EF28F9C7Q30491310-DD3375F2-F67F-4463-A0AB-67C1EEDB7409Q30835228-0C9CA966-5D59-4C2E-9269-B9E14653555DQ33235110-C8A97E39-0109-4069-9EDF-3234F94306CEQ33605308-CF3FA72F-EE16-436F-B221-9628AC114C6DQ33621692-2DDFB656-4033-4723-9233-693DAF3FEF13Q34249753-D2482895-ED76-4620-86FD-7A7F1B170724Q34252367-FCE2AF2D-373D-4138-BC84-D1435F442E2DQ34274859-68BCA24E-9870-4FB4-B47C-5FB9E680813AQ34379248-937BCDB2-3E92-4C57-8B99-337D793B7195Q34415943-D063F9E6-DF62-48EC-8A80-EF7DDF437981Q34486230-F21A971B-3666-40CC-86FA-A87FC9B8C6BFQ34603527-AE4F817F-ECF9-4683-90A7-B3E9808F3582Q34807152-1EB600FC-56DC-426B-97AD-93FF215104FFQ34879109-BC41BF10-6A3B-4EC1-814B-BCE4481A30CDQ34965927-DA89B8FC-9A93-4CE1-BF76-7DC0703ECE29Q35157252-23488D47-4AC5-41C9-80C4-2D080C498506Q35202584-7581E357-3F9E-427C-B7E4-949D48755B29Q35252525-203AFD10-529A-4B6C-B415-ADAC3E624E08Q35390239-55D5F624-C5E0-4902-BFD5-7DBE3740F81CQ35505540-AA586D97-053B-439C-AA81-AD2572594286Q35841673-7EA24EC8-DFA9-4104-8048-3784B0A08230Q35898775-C921088E-291A-4FA9-B993-5F1F713F99DFQ36033253-A0F26E05-95BF-4CE4-88B9-FE66EDF15F7AQ36302850-40ADE3E1-FF9C-4258-95A6-242C1B086550Q36488025-C0D7A9B3-E3F7-49BF-8D66-F4BB59C488A6Q36488206-B477D960-9CFD-4C8D-B2EE-B842A053857DQ36625363-E0EE7AEF-0386-4F04-AF63-F2B56CECF5A4Q36648517-218AC44C-BA98-4F36-99DC-CBB621393414Q36823176-6D0A3739-58A2-46B4-A2F5-C6A7921ACAFAQ36828285-D48AEEAC-39E4-4077-B3E0-3D6C7CED7FDAQ36858373-5A465536-E849-4F5F-8A76-B99413B6D9B3Q36886717-DC42BB41-8F0C-4306-BEC6-6344C1449BCFQ37075894-426E22BE-E3AE-46D5-883D-AA935AA418A0
P2860
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A meta-analysis and critical r ...... hrenia: opening a closed book.
@ast
A meta-analysis and critical r ...... hrenia: opening a closed book.
@en
type
label
A meta-analysis and critical r ...... hrenia: opening a closed book.
@ast
A meta-analysis and critical r ...... hrenia: opening a closed book.
@en
prefLabel
A meta-analysis and critical r ...... hrenia: opening a closed book.
@ast
A meta-analysis and critical r ...... hrenia: opening a closed book.
@en
P1476
A meta-analysis and critical r ...... hrenia: opening a closed book.
@en
P2093
Aaron L Mishara
Terry E Goldberg
P304
P356
10.1016/J.BIOPSYCH.2004.01.027
P407
P577
2004-05-01T00:00:00Z